Valbiotis develops nutrition solutions to prevent cardio metabolic diseases and provides nutritional support for patients.
Valbiotis has raised $9.8M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in November 2022.
Valbiotis's investors include Sofimac Investment Managers.
Valbiotis is headquartered in La Rochelle, France.
Valbiotis develops nutrition solutions to prevent cardio metabolic diseases and provides nutritional support for patients.
Valbiotis is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Valbiotis — Funding & Investors." VCBacked, November 8, 2022, https://www.vcbacked.co/company/valbiotis. Accessed August 14, 2026.
VCBacked. (2022). Valbiotis — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/valbiotis
{{cite web |title=Valbiotis — Funding & Investors |url=https://www.vcbacked.co/company/valbiotis |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated